tbuckley/cabot-search huggingface dataset:
987P Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Authors: None W. kang, Y.J. Kim, S.U. Kim, Y-S. Seo, J. Kim, J-H. Kim, S.Y. Park, Y-H. Baek, K. Kim, H.L. Lee, K.T. Yoon, H. Kim, J.Y. Cheong, J.S. Hwang, J.H. Kim, K.M. Kim, P.S. Sung, J.J. Kim, D-Y. Kim
Journal: Annals of Oncology (2023)
1040P Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Authors: Y. Kuboki, S. Kitano, M. Ikeda, T. Koyama, H. Mizugaki, T. Narikiyo, Y. Yamaguchi, T. Ishida, R. Takubo, C. Ogami, M. Sekiya, Y. Nakagawa, N. Yamamoto
Journal: Annals of Oncology (2023)
985P Characteristics and outcomes in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who initiated second-line (2L) therapy after receiving first-line (1L) atezolizumab plus bevacizumab (atezo+bev) and in those who did not
Authors: A. Singal, K. Ozgurdal, Z. Vassilev, F. Pisa, W. John, P. Pathak, S. Gordon, X. Pan
Journal: Annals of Oncology (2023)
1023MO Decoding immunotherapy resistance: A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes
Authors: K. Bernatowicz, F. Grussu, C. Tozzi, A. Voronova, M. SANZ, M. Vieito Villar, G. Alonso Casal, V. Galvao, A. Oberoi, I. Braña, O. Saavedra Santa Gadea, E. Muñoz Couselo, None G. serna, A.B. Moreno, M. Rotxes, J. Tabernero, R.D.A. Toledo, P.G. Nuciforo, E. Garralda, R. Perez Lopez
Journal: Annals of Oncology (2023)
1008P The safety and efficacy of PD-1 inhibitor (Sintilimab) combined with conventional transarterial chemoembolization (cTACE) for the initial treatment of the stage BCLC B hepatocellular carcinoma (HCC) beyond up-to-seven criteria
Authors: Z. Wang, J. Zhou, L. Zhang, X. Xu, Z. Ren, J. Fan
Journal: Annals of Oncology (2023)
1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Authors: A.N. Starodub, S-B. Kim, D. Davar, J. Powderly, A.G. Hill, O. Yeku, N. Gabrail, C. Krapp, S. Pihl, M. Chen, S. Slavsky, D. Torrejon Castro, S.M. Singel, V. Kwatra
Journal: Annals of Oncology (2023)
974P The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Authors: G. Lv, T. Yang, D-Q. Liu, H-D. Jia, H. Wang, N. Wang, W. Qiu, Z. Fan, F. Shen, C. Li, M. Wang
Journal: Annals of Oncology (2023)
1032P A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Authors: Z. Peng, B. Liu, J. Wei, C. Wang, Y. Zhang, Y. Shu, L. Liu, J. Li, X. Zhu, Q. Fan, Y. Feng, Y. Zhang, Y. Luo, L. Li, H. Zhou, L. Shen
Journal: Annals of Oncology (2023)
982P Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Authors: Z. Zhang, G. Shao, C. Yu, J. Ji, None J. ma, None X. guo, Z. Zhao, C. Shi, H. Zhang, P. Ji, Q. Sun
Journal: Annals of Oncology (2023)
1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
Authors: J.S.W. Borgers, D. Lenkala, B. McCarthy, V. Kohler, S. Hymson, K. Esaulova, O. Finney, K. Balogh, S. Klobuch, C. Nijenhuis, R.B. Gaynor, M. DeMario, J.B.A.G. Haanen, M.M. van Buuren
Journal: Annals of Oncology (2023)
998P Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Authors: R-Y. Mai, L. Guo, R. Liang, X-B. Wang, T. Bai, J. Chen, Z. Lin, Y. Lin, G. Wu, B-D. Xiang, L. Ma, F-X. Wu, L-Q. Li, W-X. Guo, J. Ye
Journal: Annals of Oncology (2023)
1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Authors: A.J. Olszanski, J.J. Luke, P.M. LoRusso, G.S. Falchook, P.L. Bedard, R.E. Sanborn, S.P. Patel, D. Orr, J.P. Gibbs, C. Li, Y-C. Huang, R. Gregory, S. Perera, R. Xu, A. Joshi, M.Y. Lee, J. Raizer, X. Gao
Journal: Annals of Oncology (2023)
970P Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Authors: C-K. Lee, C. Yoo, S.J. Park, H. Kim, K. Korphaisarn, J.W. Kim, S-C. Chen, I. Kim, M. Kim, S.L. Chan, J.W. Kim, D.W.M. Tai, S.B. Oh, C-T. Chen, W.K. Bae, H. Kim, J.Y. Hong, H.J. Choi, H.J. Chon, M.A. Lee
Journal: Annals of Oncology (2023)
983P Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Authors: M. Zhao, N. Lyu, S. Zhong, J. Yi, S. Chen, Y. Hu, X. Jiang, X. Wang, Q. Chen
Journal: Annals of Oncology (2023)
1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
Authors: J.W. Riess, E. Cohen, J. Spicer, P.H. Shaw, J. Rubio Perez, L. Medina Rodríguez, M.F. Chaney, S. O'Neill, A.W. Pedersen, D. McDowell, E. Ehrnrooth, P. Garrido Lopez
Journal: Annals of Oncology (2023)
886P Prospective evaluation of dynamic changes of cell-free HPV-DNA (cfHPV-DNA) in locoregional HPV associated (HPV+) oropharyngeal cancer (OPC) treated with neoadjuvant chemotherapy and response-stratified treatment
Authors: A. Rosenberg, E. Izumchenko, A. Juloori, Z. Gooi, A. Pearson, A. Vannier, E. Blair, F. Jones, A. Starus, M. Lingen, N. Cipriani, R. Hasina, J. Chin, D. Haraf, E. Vokes, N. Agrawal
Journal: Annals of Oncology (2023)
900P COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Authors: A. Psyrri, M. Kyprianou, S. Cavalieri, M. Oliva Bernal, J. Rogado, C. Pena, L. Iglesias, N. Baste Rotllan, B. Castelo, G. Fountzilas, C. Martinez-Vila, M. Cucurull Salamero, S. Triaridis, I. Diaz de Corcuera Frutos, E. Unal, M.L.K. Chua, None H. hamid, N.F. Saba, R. Mesia Nin, L.F.L. Licitra
Journal: Annals of Oncology (2023)
889P CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Authors: G. Bruixola, D. Dualde, V. Agusti, A. Nogué Infante, A. Jiménez Pastor, F. Bellvis Bataller, A. Fuster-Matanzo, B. Soriano, J.P. Fernández, J.A. Molina, N. Grimalt Ferrer, A. Viala Monleon, V. Segui, L.M. Candia, C. Alfaro-Cervello, N. Tarazona Llavero, Á. Alberich Bayarri, A. Cervantes
Journal: Annals of Oncology (2023)
899P Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Authors: B. Vilar Anglada, P. Guillén Sentís, C. Castillo Manzano, J. Brenes Castro, F. Morey, S. Tous, B. Quirós, M. Plana Serrahima, A. Lozano, I. Linares Galiana, E. Vilajosana, C. Godino, M. Labori, M. Goma, A. Marí, O. Bermejo, M. Fulla, L. Alemany, M. Oliva
Journal: Annals of Oncology (2023)
907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Authors: L.D. Locati, L. De Cecco, F. Bonini, E. Orlandi, F. Sottotetti, L.F.L. Licitra, R. Ferrarotto
Journal: Annals of Oncology (2023)
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Authors: S. Laban, L. Hofmann, A.C. Betzler, K. Payer, M. Bens, J. Truong, A. von Witzleben, J. Thomas, J.M. Kraus, R. Kalaajieh, D. Huber, J. Ezić, J. Benckendorff, J. Greve, C.H.H. Ottensmeier, H.A. Kestler, T.K. Hoffmann, M-N. Theodorakis, C. Brunner, T. Abou Kors
Journal: Annals of Oncology (2023)
911P Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Authors: J.S.H. Tan, J. Neo, E.H.W. Ong, W.M. Chow, K.W. Fong, Y.L. Soong, S.Y. Sin, D.S.W. Tan, M-K. Ang, S.H. Tan, D.W-T. Lim, M.L.K. Chua
Journal: Annals of Oncology (2023)
902P Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Authors: C. Suzuki, N. Yamamoto, M. Yamamoto, Y. Kishimoto, S. Hiraoka, R. Nakashima, K. Honda, M. Nomura, M. Kitamura, M. Muto, S. Morita, K. Omori
Journal: Annals of Oncology (2023)
906P Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Authors: S. Rack, D. Morgan, S. Kirkham, L. Feeney, K. Patel, E. Heathcote, K.J. Harrington, R. Metcalf, T. Hussell
Journal: Annals of Oncology (2023)
888P Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Authors: M. Verheij, A. Navran, A. Al-Mamgani, H. Elzinga, R. Kessels, C. Vens, M. Tesselaar, M. van den Brekel, R. de Haan, B. van Triest
Journal: Annals of Oncology (2023)
903P AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Authors: R. Ferrarotto, P. Bobbili, D.W. Bowles, C. Even, G. Gordon, A. Gutierrez, R. Metcalf, J. Muzaffar, C. Nguyen, M. Oliva, C.A. Perez, C. Rodriguez, S.R. Sendhil, E. Winquist, L.J. Wirth, B. Xia, J. Yovell, A.L. Ho
Journal: Annals of Oncology (2023)
891P Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Authors: N. Ngamphaiboon, A. Dechaphunkul, C. Vinayanuwattikun, P. Danchaivijitr, T. Thamrongjirapat, A. Prayongrat, T. Dechaphunkul, R. Jiratrachu, P. Pattaranutaporn, C. Jiarpinitnun, J. Setakornnukul
Journal: Annals of Oncology (2023)
881P SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Authors: I. Vasiliadou, C. Cattaneo, R. Henley-Smith, H. Gregson-williams, L. Colins, J. Davis, G. Wojewodka, C. Regenbrecht, L. Wedeken, T. Guerrero Urbano, J-P. Jeannon, S. Connor, A. Azad, M. Arshad, T. Ng, A. Kong
Journal: Annals of Oncology (2023)
879P Targeted next-generation sequencing reveals CDKN2A alterations as a prognostic biomarker in recurrent or metastatic head and neck squamous cell carcinoma mostly treated with immune checkpoint inhibitors
Authors: Y. Guo, L. Xue, W. Tang, J. ZHou, J. Xue, Q. Li, X. Ge, F. Lin, W. Zhao
Journal: Annals of Oncology (2023)
876P Gene expression analysis in oral potentially malignant disorders (OPMD) with dysplasia identifies patients at high risk of malignant transformation
Authors: L. De Cecco, L. Lorini, M. Tomasoni, A. Paderno, D. Lenoci, A. Licata, E. Moresco, C. Romani, D. Mattavelli, C. Magri, S. Battocchio, A. Bozzaola, C. Gurizzan, M. Facchetti, A. Oberti, C. Piazza, S. Koljenovic, P. Saintigny, P. Bossi
Journal: Annals of Oncology (2023)
901P Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Authors: A. Desilets, C. Hermosilla Samayoa, M. Tonneau, O. El Ouarzadi, M. De Figueiredo Sousa, H. Bahig, J. Malo, W. Belkaid, M. Benlaïfaoui, M. Ponce, L. Derosa, E. Filion, P.F. Nguyen-Tan, D. Charpentier, F.M. Aubin, Z. Hamilou, R. Jamal, B. Routy, M. Messaoudene, D. Soulieres
Journal: Annals of Oncology (2023)
908P Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Authors: C.O. Hoff, L.G. de Sousa, F. Bonini, E. Dal Lago, K. Wang, J. Mota Siqueira, M.A. Cortez, Y. Mitani, A. Purushothaman, A. El-Naggar, R. Ferrarotto
Journal: Annals of Oncology (2023)
895P Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial
Authors: H. Wang, X. Wang, X. Zhou, Y. Li, P. Wang, X. Zhang, Y. Pan, R. Cheng, J. Xiao
Journal: Annals of Oncology (2023)
912P Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Authors: Q. Cai, Q. Zou, Y. Zhang, Y. Xia, P. Liu, N. Su, J. Wang, X. Tian
Journal: Annals of Oncology (2023)
897P Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Authors: D.K. Shah, K. Prabhash, V.M. Patil, A.C. Singh, N.S. Menon
Journal: Annals of Oncology (2023)
898P Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head &amp; neck cancer (LAHNC)
Authors: N. Dunlap, C. Anderson, C. Lee, J. Kelley, G. Walker, V. Bar-Ad, D. Miller, V. King, A. Peddada, D. Ciuba, F. Vincent, B. Muzyka, A. Gillespie-Twardy, S. Sonis, E. Kennedy, D. Saunders
Journal: Annals of Oncology (2023)
887P Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Authors: C. Le Tourneau, Z. Takacsi-Nagy, X. Liem, V. Calugaru, V. Moreno Garcia, E. Calvo, S. Salas, B. Doger de Spéville, A. Dubray-Vautrin, X. Mirabel, N. Badois, A. Chilles, N. Fakhry, S. Wong Hee Kam, A. Debard, A. Serra, L. Finzi, O.I. Vivar, L.A. Farber, M. Lesnik
Journal: Annals of Oncology (2023)
904P Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Authors: J.A.M. Weijers, G.W. Verhaegh, C.M.L. Driessen, I.V. Engen-van Grunsven, L.A. Devriese, M. Slingerland, A. Hoeben, J.A. Schalken, C.M.L. Van Herpen
Journal: Annals of Oncology (2023)
909P TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Authors: J. Mota Siqueira, Y. Mitani, M.L. Marques-Piubelli, C.O. Hoff, F. Bonini, A. Purushothaman, D. McGrail, A. El-Naggar, R. Ferrarotto
Journal: Annals of Oncology (2023)
880P ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Authors: N. Würdemann, C. Alidousty, O.G. Siefer, C.U. Hübbers, S. Silling, D. Schafigh, R. Bacher, R. Büttner, M. Dietlein, U. Wieland, A. Drzezga, M. Schlamann, A. Quaas, C. Wittekindt, I. Demers, E-J. Speel, S. Wagner, J. George, A. Schultheis, J.P.P. Klussmann
Journal: Annals of Oncology (2023)
699P Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Authors: E. Vita, F. Monaca, L. Mastrantoni, G. Piro, G. Moretti, I. Sparagna, A. Stefani, A. Vitale, G. Trovato, M. Di Salvatore, M. Sanguinetti, A. Urbani, L. Richeldi, C. Carbone, E. Bria, G. Tortora
Journal: Annals of Oncology (2023)
748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Authors: E. Colomba, D. Lorusso, H. Mackay, R. Moore, K. Yonemori, Y.M. Kim, U.A. Sanli, R. Xie, G. Barresi, J. McKenzie, V. Makker
Journal: Annals of Oncology (2023)
710P A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Authors: E. Crimini, A. Esposito, C. Belli, R. Scafetta, R. Scalia, G. Castellano, E. Giordano, J. Katrini, L. Ascione, M. Repetto, L. Boscolo Bielo, A. Marra, D. Trapani, T. Profeta, G. Varano, D. Maiettini, P. Della Vigna, F. Orsi, C. Criscitiello, G. Curigliano
Journal: Annals of Oncology (2023)
751P Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Authors: J. Sehouli, C. Krause, D. Zocholl, J. Boer, F. Saner, C. Liebrich, D.L. Stanculeanu, T.A. Zwimpfer, A. Nienhaus, A.S. Gheorghe, M. Mueller, P. Lammert, V. Heinzelmann-Schwarz, C. Müller, M.L. Heubner, B. Melekian, M. Keller, L. Chinczewski
Journal: Annals of Oncology (2023)
706P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Authors: K. Puco, E.S. Samdal Steinskog, E.S. Blix, S. Brabrand, M. Colban, L. Fagereng, A. Flobak, C. Fredvik Torkildsen, T.K.K. Guren, A. Haug, K.A.M. Johansson, S. Meltzer, P. Niehusmann, I.A. Oppedal, H.E.G. Russnes, K. Tasken, S. Smeland, A. Helland
Journal: Annals of Oncology (2023)
681P First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Authors: C-C. Lin, R.E. Schneider, M. Gutierrez, L. Shen, B. Gao, K. Chung, D.B. Doroshow, M. Millward, C-Y. Hsieh, C. Xu, S.X. Cai, Y.E. Tian, L. Liu, C. Shen, B. Li, Y. Tan, C. Zhang, L. Li, M. Ma, X. Chen
Journal: Annals of Oncology (2023)
698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
Authors: N. Choudhury, P. Jain, A. Dowlati, J. Thompson, M.L. Johnson, H. Mamdani, R.E. Sanborn, E.L. Schenk, R. Aggarwal, K. Sankar, L.N. Walker, B. Anand, H. Beltran
Journal: Annals of Oncology (2023)
712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Authors: A. Alistar, D. Mahalingam, M. Barve, M. Borad, H. Babiker, H. Xie, B. Choi, J. Ahn, J. Choi, K. Ahn, S. Ryu, J. Kim, D. Yu, S-J. Lee, B. Jeon, S. Proniuk, J. Kim, K. Nam, A.B. El-Khoueiry
Journal: Annals of Oncology (2023)
720TiP Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
Authors: A-R. Naqash, J.S. Wang, C.A. Perez, J.T. Henry, B. Bashir, A. Panneerselvam, S. Markova, R.S. Cheung, D.R. Spigel
Journal: Annals of Oncology (2023)
718TiP DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Authors: E. Moser, M. Salkeni, A. Marabelle, D. Kientop, J. Mumm
Journal: Annals of Oncology (2023)
756P First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Authors: G.E. Konecny, A.E. Wahner Hendrickson, B. Winterhoff, A. Machado, C. Chander, S. Davenport, S. Bilic, L-L. Miller, A. Chung, M.F. Press, S. Letrent, D. Slamon
Journal: Annals of Oncology (2023)

CLDN6 is expressed at high levels in multiple cancers with little to no expression in normal tissues and has been implicated in the initiation, progression, and metastasis of some cancers. CLDN6 is an ideal target for development of new therapeutics. TORL-1-23 is first-in-class ADC targeting the tumor-specific antigen CLDN6. This ongoing first in human study (TORL123-001, NCT05103683) characterizes the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of TORL-1-23 in participants with advanced solid tumors. Pharmacokinetics (PK), immunogenicity and clinical efficacy are also assessed. TORL-1-23 is administered IV every 3 weeks. In Dose Escalation, cohorts up to 6 participants are evaluated at each dose level according to an accelerated titration design. In Dose Expansion, patients with CLDN6-expressing cancers will be evaluated to confirm the RP2D in ovarian cancer, NSCLC, and other CLDN6+ cancers using an IHC companion diagnostic. Doses above the historic MTD for MMAE containing ADCs are being evaluated given the favorable safety/tolerability at doses <2.4 mg/kg. 30 patients with ovarian (n=22), testicular (n=5), and endometrial (n=3) cancers were enrolled across 9 dose levels ranging from 0.2 to 3 mg/kg IV every 3 weeks (as of 01MAY2023). 93% of pts had received ≥ 3 prior lines of treatment in the metastatic setting. The most common treatment-related adverse events were Gr1/2 fatigue (n=6), anemia (n=5), and peripheral neuropathy (n=4). No DLTs were observed at doses ≤2.4 mg/kg. Sustained PK exposure of TORL-1-23 over the dosing interval and low levels of circulating MMAE are noted. Partial responses (PR) were observed in 7/22 (32%) efficacy evaluable participants with CLDN6+ disease (6 ovarian, 1 testicular) across dose levels. 3/3 (100%) participants with CLDN6+ ovarian cancer responded at the 2.4 mg/kg dose level. Data from 3 mg/kg are pending. In participants with heavily-pretreated CLDN6-expressing ovarian cancer, the novel TORL-1-23 ADC has a favorable safety/tolerability profile and encouraging antitumor activity in a phase 1 dose finding study. Further evaluation in ovarian cancer and other CLDN6+ cancers is warranted.
714TiP A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Authors: S.J. Luen, E.S. Ahern, C. Berger, J. Desai, S. Frentzas, H. Gan, M. Gualandi, B. Markman, M. Millward, A. Rafiei, B. Tran, C. Renner
Journal: Annals of Oncology (2023)
707P Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Authors: M.B.A. van der Kleij, N.A.D. Guchelaar, M. Meertens, E.L. Giraud, R.F. Bleckman, A.L.T. Imholz, A. Vulink, H-M.M.B. Otten, T.J. Smilde, M. Los, H-B. Fiebrich, P. Hamberg, F.J.E. Lubberman, S.L. Koolen, H. Gelderblom, A.K.L. Reyners, N.P. Van Erp, R.H. Mathijssen, A.D.R. Huitema, N. Steeghs
Journal: Annals of Oncology (2023)
744MO AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Authors: J-Y. Lee, L. Wu, S. Boonyapipat, H.S. Kim, J-W. Lee, L. Wang, T. Wang, D. Wang, D. Yao, H. Liu, T. Andabekov, X. Zhang, W. Wang, Y.M. Kim, K. Wang, Y. Gao, X. Mu, I. Volodymyrovych Sinielnikov
Journal: Annals of Oncology (2023)
757P The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Authors: Q. Zhang, Z. Liu, J. Zhang, J. Wang, T. Wang, J. Su, F. Shi, F. Wang
Journal: Annals of Oncology (2023)
705P TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Authors: A. Italiano, L. Belcaid, S. Cousin, K. Trin, A. Bayle, I. Soubeyran, M. Alamé, L. Blouin, E. Rouleau, L. Lacroix, D. Vasseur, C. Bellera
Journal: Annals of Oncology (2023)
711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Authors: A.J. Weickhardt, S. Frentzas, C. Lemech, J. Srimani, J. Yin, W.L. Trepicchio, C. Gorgun, G. Kichenadasse
Journal: Annals of Oncology (2023)
695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Authors: E. Garralda, A. Oberoi, T. Koyama, P. Schoeffski, P.A. Ascierto, C-C. Lin, M.H.H. Schuler, Y. Xing, S.P. Patel, V. Subbiah, N. Lewis, J.B. Lee, N.B. Hassounah, L.H. Lee, M. Roy, S. Banerjee, A. Reynolds, L. Wang Lakshman, T. Shimizu
Journal: Annals of Oncology (2023)